Cidara Therapeutics, Inc. (NASDAQ:CDTX) has analysts on the Bullish side this week.

October 13, 2018 - By olga

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Logo

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Ratings Coverage

Among 3 analysts covering Cidara Therapeutics (NASDAQ:CDTX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cidara Therapeutics had 3 analyst reports since May 10, 2018 according to SRatingsIntel. The rating was maintained by Cantor Fitzgerald with “Buy” on Thursday, May 10. The stock of Cidara Therapeutics, Inc. (NASDAQ:CDTX) earned “Buy” rating by WBB Securities on Wednesday, May 23. Below is a list of Cidara Therapeutics, Inc. (NASDAQ:CDTX) latest ratings and price target changes.

26/07/2018 Broker: Citigroup Rating: Buy Initiates Coverage On
23/05/2018 Broker: WBB Securities Rating: Buy New Target: $6.2500 Upgrade
10/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $15.0000 Maintain

The stock decreased 3.62% or $0.15 during the last trading session, reaching $3.99. About 57,653 shares traded. Cidara Therapeutics, Inc. (NASDAQ:CDTX) has declined 36.09% since October 13, 2017 and is downtrending. It has underperformed by 51.71% the S&P500.

Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of various diseases. The company has market cap of $110.44 million. The Company’s lead product candidate is CD101 IV, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious, invasive fungal infections. It currently has negative earnings. The firm also develops CD201, a novel bispecific antimicrobial immunotherapy for the treatment of multidrug-resistant gram-negative bacterial infections, including those caused by pathogens harboring the mcr-1 plasmid.

More news for Cidara Therapeutics, Inc. (NASDAQ:CDTX) were recently published by: Seekingalpha.com, which released: “Cidara up 30% premarket on mid-stage rezafungin data” on October 04, 2018. Nasdaq.com‘s article titled: “Cidara Therapeutics to Present at Two Upcoming Investor Conferences” and published on September 24, 2018 is yet another important article.

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>